Cipla Limited (CIPLA) — Financial Results | 26 July 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Cipla reported consolidated revenue of ₹3,719 crores for Q1 FY2025, up 69.9% YoY, with consolidated profit after tax at ₹316 crores, reversing a ₹49 crore loss in the prior year. The company posted a ₹316 crore profit versus ₹(49) crore loss YoY, driven by strong revenue growth and improved margins. Standalone revenue reached ₹1,169 crores, with standalone profit after tax at ₹307 crores, reflecting a 19.5% YoY increase from ₹256 crores. The results were approved by the Board on 25 July 2025 and reviewed by the Audit Committee. InvestorTakeaway: The company returned to profitability with robust top-line growth and margin expansion, signaling operational recovery.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day